Table 2.
Relapse Rates Per Patient Year Among 1,092 Patients
| Diagnosis* | Stage | No. of Patients | Relapse Rate |
|
|---|---|---|---|---|
| Years 1 and 2 | Years 3-5 | |||
| Low risk | ||||
| MPN | Any | 18 | 0.10 | 0.00 |
| CLL | CR | 9 | 0.11 | 0.14 |
| Waldenström's syndrome | Any | 10 | 0.13 | 0.06 |
| NHL | Any stage of mantle cell and low-grade; aggressive CR | 140 | 0.16 | 0.02 |
| ALL | CR1† | 28 | 0.17 | 0.04 |
| MM | CR | 38 | 0.19 | 0.06 |
| Standard risk | ||||
| CLL | No CR | 113 | 0.24 | 0.05 |
| CML | CP1 | 24 | 0.24 | 0.00 |
| MM | No CR | 179 | 0.32 | 0.17 |
| AML | CR‡ | 191 | 0.33 | 0.02 |
| MDS | RA/RARS | 30 | 0.35 | 0.00 |
| High risk | ||||
| NHL | Aggressive; no CR | 50 | 0.48 | 0.00 |
| AML | No CR; evolved from MDS | 98 | 0.65 | 0.04 |
| HL | After failed autologous HCT | 61 | 0.61 | 0.14 |
| MDS | RAEB; CMML; second | 62 | 0.65 | 0.04 |
| CML | CP2; AP; BC | 23 | 0.71 | 0.07 |
| ALL | ≥ CR2; no CR | 18 | 1.03 | — |
Abbreviations: ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; AP, accelerated phase; BC, blast crisis; CLL, chronic lymphocytic leukemia; CML, chronic myelocytic leukemia; CMML, chronic myelomonocytic leukemia; CP, chronic phase; CR, complete remission; HCT, hematopoietic cell transplantation; HL, Hodgkin lymphoma; MDS, myelodysplastic syndrome; MPN, myeloproliferative neoplasms; MM, multiple myeloma; NHL, non-Hodgkin lymphoma; RA, refractory anemia; RAEB, refractory anemia with excess blasts; RARS, refractory anemia with ring sideroblasts.
There were 243 patients in the low-risk group (53% related and 47% unrelated donors); 537 patients in the standard-risk group (58% related and 42% unrelated donors), and 312 patients in the high-risk group (54% related and 46% unrelated donors).
Before HCT, 14% of patients had minimal residual disease.
Before HCT, 13% of patients had minimal residual disease.